Xenon is both an old and a new anesthetic. Although its anesthetic properties have been known for more than 50 yr, it was largely forgotten until 1990, 1mainly because of its high cost. Aside from this problem, xenon possesses many of the characteristics of an ideal anesthetic. For example, its blood–gas partition coefficient is extremely small (0.115), 2yielding rapid emergence from anesthesia 3regardless of the duration of anesthesia. 4It lacks teratogenicity, 5and it produces analgesia, 6thereby suppressing hemodynamic and catecholamine responses to surgical stimulation. 7,8It is also a potent hypnotic. 9,10Unlike many conventional anesthetics, xenon does not produce hemodynamic depression in healthy humans 11and in dogs with normal hearts and with cardiomyopathy, 12at least in part because it has no actions on some important cardiac ion channels. 13,14The characteristics of xenon have been reviewed more extensively elsewhere. 15,16 

Essentially all previous studies of xenon, even in humans, have been relatively small. This issue of Anesthesiology contains the first large-scale clinical evaluation of xenon anesthesia. 17The study, conducted by Roissant et al. , 17demonstrates that xenon and nitrous oxide–isoflurane are at least equivalent in efficacy and safety. This study is undoubtedly a necessary step toward wide application of xenon. However, the real question is whether there is a true future for xenon. In light of the work by Roissant et al. , 17it is reasonable to ask this question now. During the last decade, we have accumulated considerable knowledge about the actions of xenon. However, the answer to this question is not obvious.

The Cost

Xenon currently costs approximately US $10.00 per liter. If one uses a closed breathing circuit, xenon anesthesia is not as expensive as one might expect from the price of the gas, because the amount of xenon absorbed by the tissues is small as a result of its extremely low solubility. In our simulation, based on Japanese prices, 18anesthetizing a 70-kg adult with 1 minimum alveolar concentration of xenon (71%) for 240 min using a closed circuit requires approximately 16 l of xenon and costs US $167.00 (including the costs for oxygen, muscle relaxants, and the soda lime). This may actually be an underestimate, since the closed-circuit technique requires that the breathing system occasionally be flushed and refilled to wash out nitrogen released from the patients’ body tissues. In contrast, the costs of nitrous oxide and isoflurane are US $30.00 and $74.00, respectively, if a closed-circuit technique or a total fresh gas flow rate of 3 l/min (i.e. , nitrous oxide, 2 l/min, and oxygen, 1 l/min) are used.

Obviously, this cost analysis depends on the price of xenon, which has fluctuated a great deal over the last 20 yr due to the changing balance between supply and demand within a dynamic market. The price was US $4.00 in the late 1980s, increased to US $18.00 in 1998, and then decreased to the current value of approximately US $10.00. It is difficult to predict the future cost. However, even if the price of xenon is prohibitively high at this time, technologic innovations in xenon production (and a growing market) may lead to lower costs. For example, xenon does not have to be produced de novo  but can be retrieved from the waste anesthetic gas (i.e. , recycling). Because the waste gas contains much higher concentrations of xenon (e.g. , 50 to approximately 60%) than does the air (0.087 ppm), its retrieval should be much less costly. The profit incentive may also promote international trade of xenon. Russia, for example, is a promising supplier, because the price of xenon is currently US $5.00 or less in that country.

Can't the Cost of Xenon Be Justified?

Xenon enthusiasts argue that the gas has two advantages: environmental and medical. The environmental advantage is that xenon is not a greenhouse gas and, hence, does not lead to global warming. It is also unreactive and, thus, should not affect the ozone layer, as do nitrous oxide and volatile anesthetics. However, the issue is not this simple. First, simply adopting a low-flow or closed-circuit technique can considerably reduce the negative impacts of conventional anesthetics. Second, xenon is not perfectly environmentally friendly. Producing 1 l of xenon gas requires 220 watt-hours of energy, a million times more than that for nitrous oxide, because xenon is purified by fractional distillation of the liquefied air, which involves multiple heating, cooling, and pressurization processes. 19This large energy consumption, and the resultant emission of carbon dioxide, certainly diminishes the environmental advantage of xenon. Even if xenon has measurable environmental advantages, it is very difficult to incorporate these in a cost-benefit analysis because the value of the environment differs considerably among different countries and societies. Furthermore, environmental protection is considered a “public good” in an economic sense and, thus, cannot be assigned to any individual economic entity. 20 

Does xenon have medical advantages that justify the cost? The investigations over the past decade have revealed many of its advantageous characteristics, but none of these appears sufficient to justify the cost by itself. Xenon provides faster emergence, but the difference is only a matter of minutes, and the time to ward readiness is not affected. 17A lack of cardiac depression is certainly useful, but whether this represents a real clinical benefit is unclear, particularly since we are already doing a pretty good job anesthetizing millions of patients with fragile hearts. What we really need is evidence that xenon improves outcome (i.e. , results in less morbidity and mortality). Such evidence is scarce, even for conventional anesthetics or anesthetic techniques, but xenon needs to be tested against this idealistic criterion because its cost is so high. Because the current anesthetics are so safe, it is unrealistic to expect that xenon will produce measurable improvements in the outcomes of ordinary patients. Therefore, the target population will be high-risk patients. In fact, the kinds of patients excluded from the multicenter trial conducted by Rossaint et al.  17are exactly the ones who might benefit from xenon. For example, pregnant or breast-feeding patients may benefit because xenon is low in teratogenicity and toxicity and because xenon quickly leaves the body after anesthesia. Patients with disturbed liver function and/or renal function may also benefit because of low toxicity and a lack of hemodynamic depression leading to preserved organ perfusion. 21Those with congestive heart failure may also fare better because of xenon's lack of cardiac depression. However, these patients represent only a small fraction of the total number of people requiring general anesthesia, and the reduced numbers may also have an impact on economics.


The investigations over the past decade and the current multicenter trial by Rossaint et al.  17have set the stage for us to embark on the crucial step of testing whether xenon improves outcomes in high-risk patients. Several hypotheses appear worthy of investigation. For example, does xenon better preserve the function of vital organs such as the liver and kidneys in patients who have preexisting dysfunction in these organs? Does xenon facilitate recovery of trauma patients in the shock state by its lack of hemodynamic depression, leading to better perfusion of vital organs? Does xenon improve outcome in patients undergoing major surgery by providing more optimal hemodynamics? §Before answering these questions, we cannot make a convincing conclusion as to whether xenon is a stranger (after which the gas is named) or a friend to anesthesiologists.

Lachmann B, Armbruster S, Schairer W, Landstra M, Trouwborst A, Van Daal GJ, Kusuma A, Erdmann W: Safety and efficacy of xenon in routine use as an inhalational anaesthetic. Lancet 1990; 335: 1413–5
Goto T, Suwa K, Uezono S, Ichinose F, Uchiyama M, Morita S: The blood-gas partition coefficient of xenon may be lower than generally accepted. Br J Anaesth 1998; 80: 255–6
Goto T, Saito H, Shinkai M, Nakata Y, Ichinose F, Morita S: Xenon provides faster emergence from anesthesia than does nitrous oxide-sevoflurane or nitrous oxide-isoflurane. A nesthesiology 1997; 86: 1273–8
Goto T, Saito H, Nakata Y, Uezono S, Ichinose F, Morita S: Emergence times from xenon anaesthesia are independent of the duration of anaesthesia. Br J Anaesth 1997; 79: 595–9
Lane GA, Nahrwold ML, Tait AR, Taylor-Busch M, Cohen PJ, Beaudoin AR: Anesthetics as teratogens: Nitrous oxide is fetotoxic, xenon is not. Science 1980; 210: 899–901
Yagi M, Mashimo T, Kawaguchi T, Yoshiya I: Analgesic and hypnotic effects of subanaesthetic concentrations of xenon in human volunteers: Comparison with nitrous oxide. Br J Anaesth 1995; 74: 670–3
Nakata Y, Goto T, Morita S: Effects of xenon on hemodynamic responses to skin incision in humans. Anesthesiology 1999; 90: 406–10
Marx T, Froeba G, Wagner D, Baeder S, Goertz A, Georgieff M: Effects on haemodynamics and catecholamine release of xenon anaesthesia compared with total i.v. anaesthesia in the pig. Br J Anaesth 1997; 78: 326–7
Goto T, Nakata Y, Ishiguro Y, Niimi Y, Suwa K, Morita S: Minimum alveolar concentration-awake of xenon alone and in combination with isoflurane or sevoflurane. A nesthesiology 2000; 93: 1188–93
Goto T, Nakata Y, Saito H, Ishiguro Y, Niimi Y, Morita S: The midlatency auditory evoked potentials predict responsiveness to verbal commands in patients emerging from anesthesia with xenon, isoflurane, and sevoflurane but not with nitrous oxide. A nesthesiology 2001; 94: 782–9.
Luttropp HH, Romner B, Perhag L, Eskilsson J, Fredriksen S, Werner O: Left ventricular performance and cerebral haemodynamics during xenon anaesthesia. A transoesophageal echocardiography and transcranial Doppler sonography study. Anaesthesia 1993; 48: 1045–9
Hettrick DA, Pagel PS, Kersten JR, Tessmer JP, Bosnjak ZJ, Georgieff M, Warltier DC: Cardiovascular effects of xenon in isoflurane-anesthetized dogs with dilated cardiomyopathy. A nesthesiology 1998; 89: 1166–73
Stowe DF, Rehmert GC, Kwok WM, Weigt HU, Georgieff M, Bosnjak ZJ: Xenon does not alter cardiac function or major cation currents in isolated guinea pig hearts or myocytes. A nesthesiology 2000; 92: 516–22
Huneke R, Jungling E, Skasa M, Rossaint R, Luckhoff A: Effects of the anesthetic gases xenon, halothane, and isoflurane on calcium and potassium currents in human atrial cardiomyocytes. A nesthesiology 2001; 95: 999–1006
Lynch C III, Baum J, Tenbrinck R: Xenon anesthesia. A nesthesiology 2000; 92: 865–8
Dingley J, Ivanova-Stoilova TM, Grundler S, Wall T: Xenon: Recent developments. Anaesthesia 1999; 54: 335–46
Rossaint R, Reyle-Hahn M, Schulte am Esch J, Scholz J, Scherpereel P, Vallet B, Giunta F, Del Turco M, Erdmann W, Tenbrinck R, Hammerle AF, Nagele P: A multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. A nesthesiology 2003; 98: 6–13
Nakata Y, Goto T, Niimi Y, Morita S: Cost analysis of xenon anesthesia: A comparison with nitrous oxide-isoflurane and nitrous oxide-sevoflurane anesthesia. J Clin Anesth 1999; 11: 477–81
Schucht F: Production of anaesthetic gases and environment. Appl Cardiopulm Pathophysiol 2000; 9: 154–5
Stiglitz JE: Original Investigations of the Public Sector. New York, WW Norton, 1988, pp 119–44
Schmidt M, Marx T, Kotzerke J, Luderwald S, Armbruster S, Topalidis P, Schirmer U, Reinelt H: Cerebral and regional organ perfusion in pigs during xenon anaesthesia. Anaesthesia 2001; 56: 1154–9